2-[4-[2-(2,5-Dioxopyrrolidin-1-yl)oxy-2-oxoethyl]-7,10-bis(formyloxymethyl)-1,4,7,10-tetrazacyclododec-1-yl]acetic acid

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: 2-[4-[2-(2,5-Dioxopyrrolidin-1-yl)oxy-2-oxoethyl]-7,10-bis(formyloxymethyl)-1,4,7,10-tetrazacyclododec-1-yl]acetic acid
• 英文别名: 2-[4-[2-(2,5-dioxopyrrolidin-1-yl)oxy-2-oxoethyl]-7,10-bis(formyloxymethyl)-1,4,7,10-tetrazacyclododec-1-yl]acetic acid
• 化学式: C₂₀H₃₁N₅O₁₀
• 分子量: 501.5
• InChiKey: GMNUBHWZJRSEQD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -3.5
• 重原子数：
  35
• 可旋转键数：
  12
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.7
• 拓扑面积：
  167
• 氢给体数：
  1
• 氢受体数：
  14

文献信息

• CONJUGATED BISPHOSPHONATES FOR THE DIAGNOSIS AND THERAPY OF BONE DISEASES
  申请人：SCV GmbH

  公开号：US20170327520A1

  公开（公告）日：2017-11-16

  The invention relates to a compound V for complexing metallic isotopes, comprising a chelator X and one or more targeting vectors conjugated with the chelator X, said targeting vectors having the structure -L 1 -R 1 -L 2 -R 2 -L 3 -R 3 , wherein R 3 contains a bisphosphonate. A pharmaceutical consists of the compound V and a metallic isotope which is complexed with compound V.

  该发明涉及一种用于配合金属同位素的化合物V，包括螯合剂X和一个或多个与螯合剂X共轭的靶向向量，所述靶向向量具有结构-L1-R1-L2-R2-L3-R3，其中R3包含双磷酸盐。一种药物由化合物V和与化合物V配合的金属同位素组成。
• Chelated PSMA Inhibitors
  申请人：Berkman Clifford

  公开号：US20140241985A1

  公开（公告）日：2014-08-28

  Compounds as defined herein are provided which are useful in (1) diagnostic methods for detecting and/or identifying cells presenting PSMA; (2) compositions comprising a compound of the invention together with a pharmaceutically acceptable diluent; and (3) methods for imaging prostate cancer cells.

  本文提供了化合物，其用于：(1)检测和/或鉴定呈现PSMA的细胞的诊断方法；(2)包含本发明化合物和药学可接受稀释剂的组合物；以及(3)成像前列腺癌细胞的方法。
• Light-Up Probes Based On Fluorogens With Aggregation Induced Emission Characteristics For Cellular Imaging And Drug Screening
  申请人：NATIONAL UNIVERSITY OF SINGAPORE

  公开号：US20160356723A1

  公开（公告）日：2016-12-08

  The present invention is drawn toward luminogens and chemical compositions comprising a target recognition motif, a hydrophilic moiety, a linking moiety, and at least one luminogen. Additionally presented are methods of: assessing the conversion of a prodrug into its active form, assessing the therapeutic efficacy of a prodrug, detecting glutathione in a biological sample, detecting alkaline phosphatase in a sample, and conducting fluorescence imaging or magnetic resonance imaging with the use of luminogen-containing compositions.
• MODIFIED BIOTIN, STREPTAVIDIN MUTANT, AND USAGE OF THEM
  申请人：SAVID THERAPEUTICS INC.

  公开号：US20170145063A1

  公开（公告）日：2017-05-25

  An object of this invention is to provide a streptavidin mutant reduced in affinity to the naturally-occurring biotin, and to provide a modified biotin which shows a high affinity to such streptavidin mutant reduced in affinity to the naturally-occurring biotin. This invention can provide a compound composed of a dimer of modified biotin, a streptavidin mutant, and usage of them.
• US9446157B2
  申请人：——

  公开号：US9446157B2

  公开（公告）日：2016-09-20